Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to compare the survival of patients with advanced
non-small cell lung cancer (NSCLC) treated with weekly Taxoprexin in combination with
carboplatin to those treated with paclitaxel plus carboplatin in a prospectively randomized
trial. In addition, the response rate to each regimen, response duration, time to progression
and time to treatment failure will be measured. Toxicity will be evaluated and compared
between the two groups.